MHRA Sets Out 2026–2030 Strategy for Patient Involvement in UK Medical Regulation
On 5 November 2026, the Medicines and Healthcare products Regulatory Agency published its Patient and Public Involvement and Engagement Plan 2026–2030. The plan sets out how the agency intends to involve patients and the public earlier when assessing medicines and medical devices in the UK. Under the strategy, patient experiences will inform decisions about drug benefits and risks, safety reviews, medical devices, artificial intelligence, and guidance for rare diseases. The agency also plans to expand its Patient and Public Community, which was established in October 2024, to reflect broader population diversity. For everyday readers, this means patient feedback will play a direct role in how the regulator evaluates treatment risks, writes clear patient information, and sets rules for medical technology. The agency also promised to work with the National Institute for Health and Care Excellence to avoid repeating patient involvement evidence across different assessments.
What was announced
The Medicines and Healthcare products Regulatory Agency (MHRA) released its Patient and Public Involvement and Engagement Plan 2026–2030 on 5 November 2026. This plan forms part of the agency's overarching Strategy 2030 and builds on its prior 2021–2025 strategy.
The MHRA outlined five main commitments in the document:
- Expand membership of its Patient and Public Community to cover more UK demographics.
- Use deliberative engagement to collect public views on medicine risks and benefits.
- Include patients in creating clearer medical information.
- Report feedback to contributors so participants see how their input influenced regulatory work.
- Partner with the National Institute for Health and Care Excellence (NICE) to reduce duplicate submissions of patient evidence.
The agency highlighted previous work on rare diseases as an example, where an advisory group of 23 patient representatives informed draft guidance and contributed to the MHRA's Rare Disease Consortium.
What it means
The MHRA regulates medicines, medical devices, and blood components for transfusion across the UK. By bringing public feedback into early discussions, the regulator aims to base its decisions on practical everyday experiences alongside clinical data.
Patient input will apply to traditional medicine reviews, safety evaluations, regulatory policies, and newer technology areas, such as artificial intelligence and medical devices. Working alongside NICE aims to simplify how patient groups submit evidence, avoiding extra paperwork across regulatory and health technology evaluations. The MHRA's People and Public Engagement Committee will oversee the plan to monitor whether commitments are met.
What the announcement does not tell us
The announcement does not state the total budget allocated for implementing this plan over the 2026–2030 period. It does not provide specific dates or timelines for when each of the five core commitments will be completed.
The document also does not explain the exact criteria the MHRA will use to measure whether public participation has expanded successfully. Furthermore, the agency does not detail how conflict of interest checks will be managed for expanding public and patient group membership.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is gov.uk: Medicines and Healthcare products Regulatory Agency’s own. Always check the original before acting on anything here.
New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation
Opens www.gov.uk
More from gov.uk: Medicines and Healthcare products Regulatory Agency
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.